Balancing Clinical Trial and Real-World Evidence in Multiple Myeloma

In this segment, Dr. Ajay Nooka asks Dr. Surbhi Sidana to discuss how clinicians integrate evidence from randomized clinical trials with emerging real-world data when making treatment decisions in relapsed and refractory multiple myeloma. Dr. Sidana highlights that while clinical trials remain the foundation for establishing efficacy and safety, real-world evidence provides important insights into how therapies perform in broader patient populations, including those who may not meet strict trial eligibility criteria. The discussion emphasizes the complementary nature of these data sources, particularly in understanding tolerability, logistics, and outcomes in routine clinical practice. Dr. Sidana also notes that real-world data can be especially informative when evaluating treatment use in diverse or high-risk patient populations. This segment underscores the importance of integrating multiple evidence streams to support informed and individualized decision-making in multiple myeloma care.